CO2022007006A2 - Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar - Google Patents

Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar

Info

Publication number
CO2022007006A2
CO2022007006A2 CONC2022/0007006A CO2022007006A CO2022007006A2 CO 2022007006 A2 CO2022007006 A2 CO 2022007006A2 CO 2022007006 A CO2022007006 A CO 2022007006A CO 2022007006 A2 CO2022007006 A2 CO 2022007006A2
Authority
CO
Colombia
Prior art keywords
virus
present
subject
avian encephalomyelitis
avibacterium paragallinarum
Prior art date
Application number
CONC2022/0007006A
Other languages
English (en)
Inventor
Vergara Aristoteles Malo
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of CO2022007006A2 publication Critical patent/CO2022007006A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere, entre otros, a una composición inmunógena que comprende a) uno o más antígenos de avibacterium paragallinarum y uno o más antígenos del virus de la encefalomielitis aviar y uno o más antígenos del virus de la viruela aviar; y b) un portador aceptable desde el punto de vista farmacéutico. Asimismo, la presente invención se refiere a métodos para inmunizar un sujeto, que comprenden administrar a dicho sujeto la composición inmunógena de la presente invención. Además, la presente invención se refiere a métodos para tratar o prevenir signos clínicos causados por avibacterium paragallinarum, el virus de la encefalomielitis aviar y el virus de la viruela aviar en un sujeto que lo necesita, en donde el método comprende administrar al sujeto una cantidad terapéuticamente eficaz de una composición inmunógena de acuerdo con la presente invención.
CONC2022/0007006A 2019-11-29 2022-05-25 Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar CO2022007006A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19212630 2019-11-29
PCT/EP2020/083293 WO2021105167A1 (en) 2019-11-29 2020-11-25 Triple vaccine against avibacterium paragallinarum and avian encephalomyelitis virus and fowl pox virus

Publications (1)

Publication Number Publication Date
CO2022007006A2 true CO2022007006A2 (es) 2022-06-10

Family

ID=68732996

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0007006A CO2022007006A2 (es) 2019-11-29 2022-05-25 Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar

Country Status (10)

Country Link
US (1) US11541115B2 (es)
EP (1) EP4065163A1 (es)
JP (1) JP7342264B2 (es)
KR (1) KR20220110785A (es)
CN (1) CN114746113A (es)
BR (1) BR112022010147A2 (es)
CO (1) CO2022007006A2 (es)
IL (1) IL293167A (es)
MX (1) MX2022006414A (es)
WO (1) WO2021105167A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220110785A (ko) * 2019-11-29 2022-08-09 베링거잉겔하임베트메디카게엠베하 애비박테리움 파라갈리나룸 및 조류 뇌척수염 바이러스 및 계두 바이러스에 대한 삼중 백신

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
JPS515045B2 (es) * 1971-05-10 1976-02-17
JPS515045A (es) 1974-06-29 1976-01-16 Deyuaru Denshi Kk
GB8918689D0 (en) 1989-08-16 1989-09-27 Mini Agriculture & Fisheries 25/15 vaccine
JP2002154983A (ja) 2000-11-20 2002-05-28 Shionogi & Co Ltd ヘモフィルス・パラガリナルムワクチン
EP2829281B1 (en) * 2012-03-22 2019-01-16 KM Biologics Co., Ltd. Lps vaccine
CN103721253B (zh) 2014-01-02 2015-06-10 青岛易邦生物工程有限公司 一种禽脑脊髓炎和鸡痘二联活疫苗
KR20220110785A (ko) * 2019-11-29 2022-08-09 베링거잉겔하임베트메디카게엠베하 애비박테리움 파라갈리나룸 및 조류 뇌척수염 바이러스 및 계두 바이러스에 대한 삼중 백신

Also Published As

Publication number Publication date
JP7342264B2 (ja) 2023-09-11
MX2022006414A (es) 2022-06-22
US11541115B2 (en) 2023-01-03
US20210162040A1 (en) 2021-06-03
CN114746113A (zh) 2022-07-12
WO2021105167A1 (en) 2021-06-03
BR112022010147A2 (pt) 2022-08-09
EP4065163A1 (en) 2022-10-05
IL293167A (en) 2022-07-01
JP2023503430A (ja) 2023-01-30
KR20220110785A (ko) 2022-08-09

Similar Documents

Publication Publication Date Title
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
AR121361A1 (es) Vacuna
JP2018505882A5 (es)
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
UA114286C2 (uk) Спосіб лікування staphylococcus aureus
CL2021000227A1 (es) Regimen posologico del modulador del ensamblaje de la capside. (divisional de solicitud 2254-2020)
AR119159A1 (es) Tratamientos de angioedema
CO2022007006A2 (es) Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CO2021005069A2 (es) Vacuna de ibv h52 con proteína espicular heteróloga
RU2020109137A (ru) Вакцина для защиты от streptococcus suis
BR112018008835A8 (pt) composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla
CO2022016537A2 (es) Vacuna inactivada para sars-cov-2 y preparación de la misma
AR117784A1 (es) Tratamiento del sobreuso de medicación para el dolor de cabeza utilizando anticuerpos anti-cgrp o anti-cgrp-r
CO2024000377A2 (es) Novedosas composiciones líquidas orales de enzalutamida y método de fabricación de las mismas
RU2020123227A (ru) Вакцина для защиты от streptococcus suis
EA202091903A1 (ru) Кристаллическая форма битегравир-натрия